Table 5.

Cytokine release syndrome

	Patients with CRS (N = 6)
Time to onset, median (range), days	4.0 (1–8)
Duration, median (range), days	7.5 (4–11)
Oxygen supplementation, n (%)	3 (50.0)
Anti-cytokine therapy, n (%)	2 (33.3)
Tocilizumab	2 (33.3)
Corticosteroids	0
ICU admission, n (%)	0a
Hypotension that required intervention, n (%)	0
High-dose vasopressors	0
Intubated, n (%)	0

CRS cytokine release syndrome, HLH hemophagocytic lymphohistiocytosis, ICU intensive care unit, TLS tumor lysis syndrome

^aOne patient, who developed CRS (day 8–11), HLH (day 10–42), and TLS (day 11–32), and admitted to the ICU (day 12–18), is not included